Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

被引：44

作者：

Boespflug, Amelie ^{[1
,2
,3
]}

Caramel, Julie ^{[3
]}

Dalle, Stephane ^{[1
,2
,3
]}

Thomas, Luc

机构：

[1] Hosp Civils Lyon, Dermatol Unit, Lyon, France

[2] Claude Bernard Lyon 1 Univ, Dept Med, Lyon, France

[3] Claude Bernard Lyon 1 Univ, Canc Res Ctr Lyon, CNRS 5286, INSERM 1052, Lyon, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2017年 / 9卷 / 07期

关键词：

NRAS-mutant melanoma; targeted therapies; metastatic melanoma; clinical trials; ORAL MEK INHIBITOR; PHASE-II TRIAL; PROTEIN TRANSFERASE INHIBITOR; UNRESECTABLE STAGE-III; IB DOSE-ESCALATION; MUTANT MELANOMA; THERAPEUTIC TARGET; TRAMETINIB GSK1120212; CLINICAL ACTIVITY; 1ST-LINE THERAPY;

D O I：

10.1177/1758834017708160

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15-25% of all metastatic melanoma patients. It currently does not have an approved targeted therapy. Metastatic patients receive immune-based therapies as first-line treatments, then cytotoxic chemotherapy like carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment. We will review current preclinical and clinical developments in NRAS-mutated melanoma, and analyze ongoing clinical trials that are evaluating the benefit of different targeted and immune-based therapies, either tested as single agents or in combination, in NRAS-mutant melanoma.

引用

页码：481 / 492

页数：12

共 103 条

[1] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors [J].

Adjei, Alex A. ;

LoRusso, Patricia ;

Ribas, Antoni ;

Sosman, Jeffrey A. ;

Pavlick, Anna ;

Dy, Grace K. ;

Zhou, Xiaofei ;

Gangolli, Esha ;

Kneissl, Michelle ;

Faucette, Stephanie ;

Neuwirth, Rachel ;

Bozon, Viviana .

INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) :47-58

[2] MEK and the inhibitors: from bench to bedside [J].

Akinleye, Akintunde ;

Furqan, Muhammad ;

Mukhi, Nikhil ;

Ravella, Pavan ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[3] The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial [J].

Algazi, A. P. ;

Cha, E. ;

Ortiz-Urda, S. M. ;

McCalmont, T. ;

Bastian, B. C. ;

Hwang, J. ;

Pampaloni, M. H. ;

Behr, S. ;

Chong, K. ;

Cortez, B. ;

Quiroz, A. ;

Coakley, F. ;

Liu, S. ;

Daud, A. I. .

BRITISH JOURNAL OF CANCER, 2015, 112 (08) :1326-1331

[4] Developments in targeted therapy in melanoma [J].

Amann, V. C. ;

Ramelyte, E. ;

Thurneysen, S. ;

Pitocco, R. ;

Bentele-Jaberg, N. ;

Goldinger, S. M. ;

Dummer, R. ;

Mangana, J. .

EJSO, 2017, 43 (03) :581-593

[5] Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases [J].

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

McDermott, David F. ;

Kramer, Amy ;

Giles, Lydia ;

Gramlich, Kristi ;

Carberry, Mary ;

Troxel, Andrea B. ;

Letrero, Richard ;

Nathanson, Katherine L. ;

Atkins, Michael B. ;

O'Dwyer, Peter J. ;

Flaherty, Keith T. .

CLINICAL CANCER RESEARCH, 2009, 15 (24) :7711-7718

[6]

[Anonymous], ONCOLOGY WILLISTON P

[7]

Arance A, 2016, 13 INT C SMR ANN C B

[8] Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma [J].

Atefi, Mohammad ;

Titz, Bjoern ;

Avramis, Earl ;

Ng, Charles ;

Wong, Deborah J. L. ;

Lassen, Amanda ;

Cerniglia, Michael ;

Escuin-Ordinas, Helena ;

Foulad, David ;

Comin-Anduix, Begonya ;

Graeber, Thomas G. ;

Ribas, Antoni .

MOLECULAR CANCER, 2015, 14

[9] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[10] Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients [J].

Baiter, Mirjam ;

Schuler, Gerold ;

Hartmann, Arndt ;

Schneider-Stock, Regine ;

Heinzerling, Lucie .

DERMATOLOGY, 2015, 231 (02) :127-133

← 1 2 3 4 5 6 7 8 9 10 →